Ⅲa期非小细胞肺癌外科治疗策略进展

摘要/Abstract

摘要：非小细胞肺癌（NSCLC）中Ⅲa期患者占有较大比例，由于Ⅲa期NSCLC包含的临床TNM分期较复杂，且部分患者确诊时已有肿瘤侵及邻近重要器官，因此常常失去完整切除肿瘤的机会，故对于Ⅲa期NSCLC的诊疗手段国内外专家众说纷纭，新辅助治疗、手术治疗以及放化疗均在不同条件下发挥着重要作用，特别是外科手术在综合治疗Ⅲa期NSCLC方面占据着举足轻重的地位。

关键词:癌,非小细胞肺,外科手术,肿瘤分期

Abstract:Patients with Ⅲa staging have a large proportion in non-small cell lung cancer (NSCLC). These patients often lost the opportunity to complete excision of the tumor because the tumor have invaded adjacent vital organs when diagnosed. Besides, Ⅲa staging contains a lot of complicated clinical TNM stages, so, the opinions of experts at home and abroad are various about treatment of NSCLC with Ⅲa staging. Neoadjuvant therapy, surgery, radiation therapy and chemotherapy play important roles under different conditions. Especially surgery is occupying a pivotal position in comprehensive therapy of Ⅲa NSCLC.

Key words:Carcinoma, non-small-cell lung,Surgical procedures, operative,Neoplasm staging

赵青春,张子禾,陈军. Ⅲa期非小细胞肺癌外科治疗策略进展[J]. 国际肿瘤学杂志, 2019, 46(4): 243-247.

Zhao Qingchun, Zhang Zihe, Chen Jun. Surgical strategy of non-small cell lung cancer with Ⅲa staging[J]. Journal of International Oncology, 2019, 46(4): 243-247.

参考文献

［1］ Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016［J］. CA Cancer J Clin, 2016, 66(4): 271-289. DOI: 10.3322/caac.21349. ［2］ Savic M, Kontic M, Ercegovac M, et al. Comparison of mediastinal lymph node status and relapse pattern in clinical stage ⅢA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: a single center experience［J］. Thorac Cancer, 2017, 8(5): 393-401. DOI: 10.1111/1759-7714.12447. ［3］ Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw, 2018, 16(4): 412-441. DOI: 10.6004/jnccn.2018.0020. ［4］ Naqos N, Belbaraka R, El Omrani A, et al. Non-small lung cancer, ECCO/ESMO congres 2017［J］. Rev Pneumol Clin, 2018, 74(2): 61-66. DOI: 10.1016/j.pneumo.2018.02.001. ［5］ Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage Ⅲ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines［J］. Chest, 2013, 143(5 Suppl): e314S-e340S. DOI: 10.1378/chest.12-2360. ［6］ Feng W, Li Y, Shen L, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage ⅢA(N2) non-small cell lung cancer［J］. Oncotarget, 2016, 7(6): 7227-7240. DOI: 10.18632/oncotarget.6979. ［7］ Shimodaira Y, Slack RS, Harada K, et al. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial［J］. Br J Cancer, 2018, 118(3): 331-337. DOI: 10.1038/bjc.2017.423. ［8］ McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC［J］. J Thorac Dis, 2014, 6(Suppl 2): S224-S227. DOI: 10.3978/j.issn.2072-1439.2014.04.26. ［9］ NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data［J］. Lancet, 2014, 383(9928): 1561-1571. DOI: 10.1016/S0140-6736(13)62159-5. ［10］ Tong S, Qin Z, Wan M, et al. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage ⅢA (N2) non-small cell lung cancer: a systematic review and meta-analysis［J］. J Thorac Dis, 2018, 10(4): 2428-2436. DOI: 10.21037/jtd.2018.04.24. ［11］ Gonfiotti A, Viggiano D, Voltolini L, et al. Enhanced recovery after surgery and video-assisted thoracic surgery lobectomy: the Italian VATS Group surgical protocol［J］. J Thorac Dis, 2018, 10(Suppl 4): S564-S570. DOI: 10.21037/jtd.2018.01.157. ［12］ Bendixen M, Licht PB. Video-assisted thoracoscopic surgery versus open lobectomy for lung cancer: time for a randomized trial［J］. Eur J Cardiothorac Surg, 2017, 52(2): 398. DOI: 10.1093/ejcts/ezx078. ［13］ Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database［J］. Eur J Cardiothorac Surg, 2016, 49(2): 602-609. DOI: 10.1093/ejcts/ezv154. ［14］ Laursen LØ, Petersen RH, Hansen HJ, et al. Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy［J］. Eur J Cardiothorac Surg, 2016, 49(3): 870-875. DOI: 10.1093/ejcts/ezv205. ［15］ Mafé JJ, Planelles B, Asensio S, et al. Cost and effectiveness of lung lobectomy by video-assisted thoracic surgery for lung cancer［J］. J Thorac Dis, 2017, 9(8): 2534-2543. DOI: 10.21037/jtd.2017.07.51. ［16］ Taioli E, Lee DS, Lesser M, et al. Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis［J］. Eur J Cardiothorac Surg, 2013, 44(4): 591-597. DOI: 10.1093/ejcts/ezt051. ［17］张文军, 解明然, 马冬春. 全胸腔镜肺癌手术研究进展［J］. 国际肿瘤学杂志, 2015, 42(11): 860-862. DOI: 10.3760/cma.j.issn.1673-422X.2015.11.017. ［18］ Merritt RE, Hoang CD, Shrager JB. Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer［J］. Ann Thorac Surg, 2013, 96(4): 1171-1177. DOI: 10.1016/j.athoracsur.2013.05.044. ［19］ Woodard GA, Jablons DM. The latest in surgical management of stage ⅢA non-small cell lung cancer: video-assisted thoracic surgery and tumor molecular profiling［C/OL］. Am Soc Clin Oncol Educ Book, 2015: e435-e441. DOI: 10.14694/EdBook_AM.2015.35.e435. ［20］ Novellis P, Bottoni E, Voulaz E, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute［J］. J Thorac Dis, 2018, 10(2): 790-798. DOI: 10.21037/jtd.2018.01.123. ［21］ Egberts JH, Schlemminger M, Schafmayer C, et al. Robot-assisted minimally invasive lobectomy with systematic lymphadenectomy for lung cancer［J］. Zentralbl Chir, 2015, 140(1): 15-16. DOI: 10.1055/s-0034-1396253. ［22］ Veronesi G, Park B, Cerfolio R, et al. Robotic resection of Stage Ⅲ lung cancer: an international retrospective study［J］. Eur J Cardiothorac Surg, 2018, 54(5): 912-919. DOI: 10.1093/ejcts/ezy166. ［23］ Shrimali RK, Nallathambi C, Saha A, et al. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center［J］. Indian J Cancer, 2018, 55(2): 125-133. DOI: 10.4103/ijc.IJC_469_17. ［24］ Gagliasso M, Migliaretti G, Ardissone F. Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery［J］. Lung Cancer, 2017, 111: 124-130. DOI: 10.1016/j.lungcan.2017.07.013. ［25］ Reardon ES, Schrump DS. Extended resections of nonsmall cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified［J］. Thorac Surg Clin, 2014, 24(4): 457-464. DOI: 10.1016/j.thorsurg.2014.07.012. ［26］ Van Schil PE, Hendriks JM, Lauwers P. Focus on treatment complications and optimal management surgery［J］. Transl Lung Cancer Res, 2014, 3(3): 181-186. DOI: 10.3978/j.issn.2218-6751.2014.06.07. ［27］张彦军, 王军, 张小龙, 等. 393例食管胃结合部腺癌淋巴结转移的特征及其影响因素［J］. 中华肿瘤杂志, 2016, 38(9): 672-676. DOI: 10.3760/cma.j.issn.0253-3766.2016.09.007. ［28］ Mokhles S, Macbeth F, Treasure T, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymphnodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis［J］. Eur J Cardiothorac Surg, 2017, 51(6): 1149-1156. DOI: 10.1093/ejcts/ezw439. ［29］ Tantraworasin A, Saeteng S, Siwachat S, et al. Impact of lymph node management on resectable non-small cell lung cancer patients［J］. J Thorac Dis, 2017, 9(3): 666-674. DOI: 10.21037/jtd.2017.02.90. ［30］ Meng D, Zhou Z, Wang Y, et al. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis［J］. Eur J Cardiothorac Surg, 2016, 50(4): 597-604. DOI: 10.1093/ejcts/ezw083. ［31］ Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) nonsmall cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial［J］. J Thorac Cardiovasc Surg, 2011, 141(3): 662-670. DOI: 10.1016/j.jtcvs.2010.11.008. ［32］ Huang X, Wang J, Chen Q, et al. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and metaanalysis［J］. PLoS One, 2014, 9(10): e109979. DOI: 10.1371/journal.pone.0109979. ［33］ Bille A, Woo KM, Ahmad U, et al. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage Ⅰ lung cancer patients［J］. Eur J Cardiothorac Surg, 2017, 51(4): 674-679. DOI: 10.1093/ejcts/ezw400. ［34］ Wang S, Zhang B, Li C, et al. Prognostic value of number of negative lymph node in patients with stage Ⅱ and Ⅲa non-small cell lung cancer［J］. Oncotarget, 2017, 8(45): 79387-79396. DOI: 10.18632/oncotarget.18154. ［35］ Taylor MD, Lapar DJ, Thomas CJ, et al. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer［J］. Ann Thorac Surg, 2013, 96(4): 1163-1170. DOI: 10.1016/j.athoracsur.2013.04.031. ［36］ Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM Classification for Lung Cancer［J］. J Thorac Oncol, 2015, 10(12): 1675-1684. DOI: 10.1097/JTO.0000000000000678.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格.Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.